PI-RADS

PI-RADS v2.1 — prostate MRI assessment category
PI-RADS category
Tap the one that applies — its meaning opens right below.

About this score

When to use

Assigns the PI-RADS v2.1 assessment category (1–5) of a prostate lesion on multiparametric MRI, following the sequence-weighting rules for T2W, DWI/ADC and DCE. ⁦[1]⁩

Pearls and pitfalls

• The cancer detection rates per category come from a meta-analysis of 17 studies, with wide confidence intervals at the extremes. ⁦[2]⁩
• PI-RADS itself does not set a next step for a category; that also depends on PSA, PSA density, family history and prior biopsy. ⁦[1]⁩
Summarised from the numbered sources under Evidence. Check the source before relying on a statement.
Evidence
[1] Original publication
Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Defines the 1–5 assessment categories used here for a prostate lesion on multiparametric MRI, and the sequence-weighting rules (T2W, DWI/ADC, DCE) a radiologist uses to assign one.
European Urology, 2019
Open source
[2] Validation
Oerther B, Engel H, Bamberg F, Sigle A, Gratzke C, Benndorf M. Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level. Source of the patient-level cancer detection rates shown here (categories 1–5); pooled across 17 studies, with wide confidence intervals at the extremes.
Prostate Cancer and Prostatic Diseases, 2021
Open source
Last reviewed: 2026-10
Report an error in this calculator
MedScore is an educational and clinical decision-support tool. It does not provide a diagnosis, a treatment, or a drug-dosing recommendation, and it does not replace clinical judgement or local guidelines. Confirm every result against the original source before acting on it. The treating clinician remains responsible for all decisions.
Support the developer
MedScore is free on the web and made by a medical student. If it helps you, you can support its development.
Support MedScore